Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Effect of various mGlu2 and mGlu2/3 activators on parkinsonism: a sub-analysis in the MPTP-lesioned primate
Objective: To evaluate the effect of the metabotropic glutamate 2/3 (mGlu2/3) orthosteric activators (OAs) LY-354,740 and LY-404,039, as well as the effects of the metabotropic…Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Bignature in Parkinson’s Disease
Objective: We attempted to identify a metabolomic signature distinctive of Parkinson’s disease (PD) through an untargeted metabolomics approach. Background: Using an high-performance liquid chromatography targeted…the role of metabotropic glutamate receptors type 3 and 5 in parkinson’s disease: analysis of grm3 and grm5 genbe variants.
Objective: The aim of the study was to examine the association between polymorphic variants of GRM3 and GRM5 and Parkinson’s disease (PD) and motor and…SLC1A7 mutation is a cause of the autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease
Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a…Mutational effects of LRRK2 I1371V in astrocytes derived from patient specific iPSCs
Objective: To identify the LRRK2 I1371V mutational effects on astroglial biology involving glutamate metabolism and glutathione machinery. Background: The underlying cause of most of the familial…Synaptic Zn2+ Contribution to Parkinson’s Disease Pathophysiology: Pharmacological & Genetic Studies in Preclinical Mouse Models
Objective: The potential involvement of synaptic Zn2+ in development of Parkinson’s disease (PD) motor symptoms and dopaminergic neurodegeneration was investigated. Background: The progressive degeneration of…Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide
Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…mGlu3 receptors in Parkinson’s disease as a candidate target for neuroprotective therapy: evidence from preclinical studies to human genetic.
Objective: In a toxicological model of mouse parkinsonism through chronic injection of MPTP, we examined whether the presence or absence of mGlu3 receptors affected neurodegeneration…
- 1
- 2
- 3
- 4
- Next Page »